© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 19, 2021
It is not uncommon to have studies of nearly identical agents in nearly identical settings yield conflicting results, says Arjun V. Balar, MD.
March 22, 2021
Immune checkpoint blockade has revolutionized cancer therapy and led to improved outcomes and possibly even cures in the metastatic setting once thought to be unattainable.
November 22, 2020
The economic impact of the pandemic, which is still taking shape, will likely lead
to many patients being uninsured, resulting in less access to medical care and ultimately culminating in an uptick in cancer-related mortality in the years ahead.
October 25, 2020
The CLOVER-1 study is testing CLR 131 in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.